Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dalip Sethi

Cesca Therapeutics Inc., USA

Title: Clinical Applications of Autologous Bone Marrow Derived Cells

Biography

Biography: Dalip Sethi

Abstract

Cardiovascular Diseases are a major burden on healthcare in modern society. Diseases, such as Critical Limb Ischemia (CLI), are debilitating. Many of the cardiovascular ischemic disease patients have limited surgical or medical options. Regeneration of vascular system is an attractive treatment strategy and is actively pursued in various preclinical and clinical settings. One of the options in regenerative medicine is the use of autologous bone-marrow concentrate (aBMC) containing stem & progenitor cells. Autologous bone-marrow concentrate (aBMC) is derived from the bone marrow aspirate (BMA) by density centrifugation and can be delivered either intra-muscularly (IM) or intra-coronary in the affected region. The aBMC consists of a) an acellular fraction comprised of autologous plasma and the cytokines & b) Cellular Fraction which is a source of (i) proangiogenic cells such as hematopoietic stem cells, mesenchymal progenitor cells, and endothelial progenitor cells; (ii) other cells of immune system at different levels of maturity and multi-potency. The acellular and cellular components participate in tissue repair and regeneration and have made aBMC an attractive source of cells and cytokines for therapeutic angiogenesis in the treatment of ischemic diseases.

Recent Publications

1.  Ponemone et al (2017) Safety and Effectiveness of Bone Marrow Cell Concentrate in the Treatment of Chronic Critical Limb Ischemia Utilizing a Rapid Point-of-Care System. Stem Cell International 18: 1-16.

2. Sanghi et al (2016) The Autologous bone marrow concentrate enriched in progenitor cells — an adjuvant in the treatment of acute myocardial infarction. International Journal of Cardiovascular Academy 2: 77-83.

      3. Ponemone et al (2016) Enhancement of Atrophic Non-Union Fracture Healing Using Autologous Progenitor Cell-Rich Bone Marrow. HSOA Journal of Stem Cells Research, Development & Therapy. 3: 007.

      4. Sanders et al (2013) Effects of Hypoxanthine Substitution in Peptide Nucleic Acids Targeting KRAS2 Oncogenic mRNA Molecules: Theory and Experiment. J. Phys. Chem. B 117(39): 11584-11595.

Sethi et al (2012) Receptor-specific peptides for targeting of liposomal, polymeric, and dendrimeric nanoparticles in cancer diagnosis and therapy. Current Molecular Imaging, 1(1): 3-11